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Cryptococcus neoformans is a ubiquitous environmental fungus that can cause life-threat-
ening meningitis and fungemia, often in the presence of acquired immunodeficiency syn-
drome (AIDS), liver cirrhosis, diabetes mellitus, or other medical conditions. To distinguish
risk factors from comorbidities, we performed a hospital-based, density-sampled, matched
case-control study.
Methods
All new-onset cryptococcal meningitis cases and cryptococcemia cases at a university hos-
pital in Taiwan from 2002–2010 were retrospectively identified from the computerized inpa-
tient registry and were included in this study. Controls were selected from those
hospitalized patients not experiencing cryptococcal meningitis or cryptococcemia. Controls
and cases were matched by admission date, age, and gender. Conditional logistic regres-
sion was used to analyze the risk factors.
Results
A total of 101 patients with cryptococcal meningitis (266 controls) and 47 patients with cryp-
tococcemia (188 controls), of whom 32 patients had both cryptococcal meningitis and cryp-
tococcemia, were included in this study. Multivariate regression analysis showed that AIDS
(adjusted odds ratio [aOR] = 181.4; p< 0.001), decompensated liver cirrhosis (aOR = 8.5;
p = 0.008), and cell-mediated immunity (CMI)-suppressive regimens without calcineurin in-
hibitors (CAs) (aOR = 15.9; p< 0.001) were independent risk factors for cryptococcal men-
ingitis. Moreover, AIDS (aOR = 216.3, p< 0.001), decompensated liver cirrhosis (aOR =
23.8; p< 0.001), CMI-suppressive regimens without CAs (aOR = 7.3; p = 0.034), and auto-
immune diseases (aOR = 9.3; p = 0.038) were independent risk factors for developing cryp-
tococcemia. On the other hand, diabetes mellitus and other medical conditions were not
found to be risk factors for cryptococcal meningitis or cryptococcemia.
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Conclusions
The findings confirm AIDS, decompensated liver cirrhosis, CMI-suppressive regimens with-
out CAs, and autoimmune diseases are risk factors for invasive C. neoformans diseases.
Introduction
Cryptococcus neoformans is a pathogenic fungus that causes life-threatening meningitis, the
first case of which was reported in 1905 [1]. C. neoformans is ubiquitous [2]. The Centers for
Disease Control and Prevention (CDC) of the United States estimated that there are approxi-
mately one million new cryptococcal meningitis cases every year worldwide, with more than
70% of these cases occurring in sub-Saharan Africa [3]. C. neoformans infection is therefore an
important global health concern [4].
Current understanding of the pathogenesis of invasive cryptococcal diseases is primarily
based on clinical case series [5–11] and mouse experiments [12–17], which suggest that host
conditions that impair cell-mediated immunity (CMI) (e.g., human immunodeficiency virus
[HIV] infection with acquired immunodeficiency syndrome [AIDS], immunosuppressive ther-
apy) play a critical role. Liver cirrhosis has also been reported as a condition that may increase
the risk of cryptococcosis [18]. Other reported possible risk factors include diabetes mellitus,
lymphoproliferative malignancy, hematological malignancy, cancer, autoimmune diseases, and
lung diseases [19–21]. However, ascertainment of a condition as a risk factor for a disease re-
quires either a cohort study (to compare the incidence of disease between those with the condi-
tion and those without) or a case-control study (to compare the proportion of the condition
between those with the disease and those without), in order to distinguish true risk factors
from comorbidities. To date, no cohort study or case-control study has been conducted to ex-
amine the risk factors of invasive C. neoformans diseases.
The first case of cryptococcal meningitis in Taiwan was diagnosed in 1957 [22]. Large clini-
cal case series on cryptococcal meningitis [23,24], cryptococcemia [25] and cryptococcal dis-
eases [26] reported high rates of HIV/AIDS, immunosuppressive therapy, decompensated liver
cirrhosis, malignancy, diabetes mellitus, and kidney diseases among the case patients. To dis-
tinguish risk factors from comorbidities, we performed a hospital-based, retrospective, density-
sampled, matched case-control study.
Methods
Study Setting
This study was conducted at National Taiwan University Hospital (Taipei, Taiwan), a universi-
ty-affiliated medical center with a 2,200-bed capacity, which provides both primary and tertiary
referral care in northern Taiwan.
Study Design
This was a retrospective, density-sampled, case-control study. Patients with cryptococcal men-
ingitis or cryptococcemia who were diagnosed and hospitalized during 2002–2010 (cases) were
compared with those who were hospitalized during the same time period but did not have
cryptococcal meningitis or cryptococcemia (controls). The cases and controls were matched
according to admission date, age, and gender.
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Ethical Statement
Patient medical records were retrospectively reviewed to obtain information on diagnosis, sites
of C. neoformans infection, and potential risk factors. All personal information was anon-
ymized. The study procedures were reviewed and approved by National Taiwan University
Hospital’s institutional review board (No. 201101083RC). The institutional review board ap-
proved the exemption of informed consent.
Recruitment of Cases
All of the patients with the ICD-9 diagnostic code 117.5 (cryptococcal diseases) upon either ad-
mission or discharge from January 1, 2002 to December 31, 2010 were identified using a com-
puterized registry of inpatients. The patients’ medical records and microbiological reports were
reviewed. All of the new-onset cases of C. neoformansmeningitis (cryptococcal meningitis,
confirmed by cerebrospinal fluid [CSF] culture) or C. neoformans fungemia (cryptococcemia,
confirmed by blood culture) were included in the present study.
Selection of Controls
The controls were selected from inpatients who did not have cryptococcal meningitis or cryp-
tococcemia; they were individually matched to each case by admission date, age (within a 5-
year range), and gender at a 2:1 (cryptococcal meningitis) or a 4:1 (cryptococcemia) ratio. We
first obtained the list of 600,782 admissions during the period from January 1, 2002 to Decem-
ber 31, 2010 using a computerized registry of inpatients. We then randomly selected controls
for each case from the inpatients who met the matching criteria, using a random number
generator.
Data Collection
The medical records were systematically reviewed for information regarding age, gender, and
the presence of underlying diseases or conditions before the onset of invasive cryptococcal dis-
eases. We assumed an induction time (i.e., the minimum time needed for a causal factor to in-
duce the disease) of one month. Only those conditions that had been present at least one
month prior to the onset of the cryptococcal diseases were included in this study.
The data were collected using a standardized recording format, which included items re-
garding the presence or absence of the following conditions: AIDS, decompensated liver cir-
rhosis, uremia, cytotoxic chemotherapy, CMI-suppressive therapy, organ transplantation,
diabetes mellitus, lymphoma, leukemia/myeloma, solid cancer, other malignancies (e.g., gastro-
intestinal stromal tumor [GIST], sarcoma, thymoma), autoimmune diseases, cardiovascular
disease, chronic obstructive pulmonary disease, asthma, bronchiectasis, pneumoconiosis, and
gastrointestinal diseases. All of the data were independently verified by a second researcher.
In addition, the medical records were reviewed for a history of close contact with pigeons
before the onset of the invasive cryptococcal diseases, including raising pigeons or visiting pi-
geon farms, if this information was recorded.
Definitions
AIDS was defined using the CDC’s 1993 revised case definition [27]. Liver cirrhosis was con-
sidered to be decompensated if the Child-Pugh score [28] was B or C. CMI-suppressive therapy
was defined to include corticosteroids, azathioprine, mycophenolate mofetil, cyclosporine,
tacrolimus and other immunosuppressive drugs that inhibit T-cell functions. CMI-suppressive
therapy was further classified to stipulate whether a regimen was prescribed with or without
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calcineurin inhibitors (CAs) (cyclosporine or tacrolimus), which have direct in vitro antifungal
activity against C. neoformans [29]. Diabetes mellitus was defined as having a fasting plasma
glucose level 126 mg/dL, having a random plasma glucose level 200 mg/dL, or already re-
ceiving antidiabetic agents or insulin to control sugar [30]. Uremia was defined as end-stage
renal disease with uremic symptoms or as receiving dialysis for more than three months. Auto-
immune diseases included systemic lupus erythematosus, rheumatoid arthritis, dermatomyosi-
tis, and pemphigus, among others.
Statistical Analyses
Statistical analyses were performed using SAS 9.2 (SAS Institute, Cary, North Carolina, USA).
When two proportions were being compared, a chi-square test was used. Fisher’s exact test was
used when any value in the cells of the contingency table was smaller than five. Between-group
differences for continuous data were compared using Wilcoxon rank sum test. Conditional lo-
gistic regression was used to analyze the risk factors. The exact method was used. All variables
with p< 0.10 in the univariate analysis were included in the maximum model and underwent
stepwise selection during the multivariate analyses. All statistical tests were two-tailed, and p<
0.05 was considered statistically significant.
Results
Cases
From January 1, 2002 through December 31, 2010, a total of 276 inpatients at National Taiwan
University Hospital had the ICD-9 diagnostic code 117.5 upon admission or discharge. Of
them, 116 had new-onset cryptococcal meningitis (n = 101) or new-onset cryptococcemia (n =
47), including 32 who had simultaneous cryptococcal meningitis and cryptococcemia. The re-
maining 160 patients did not meet the inclusion criteria, including those with pulmonary cryp-
tococcosis (n = 120), other local involvement (n = 3), non-Cryptococcus neoformans fungemia
(n = 1), an unspecified diagnosis (positive for serum cryptococcal antigen, but without a culture
or histopathological confirmation; n = 17), an incomplete work-up (n = 3), an old diagnosis
(n = 10), or a mis-coding (n = 6). Fig. 1 shows the flow chart of the recruitment of cases.
Controls
A total of 326 controls were randomly selected from the 600,782 admissions during the period
from January 1, 2002 through December 31, 2010, including 188 controls who were matched
to the 47 patients with cryptococcemia (at a 4:1 ratio) and the 138 controls who were matched
to the 69 patients who had cryptococcal meningitis but did not have cryptococcemia (at a 2:1
ratio).
Epidemiologic Characteristics
Table 1 shows the characteristics of cryptococcal meningitis and cryptococcemia cases, includ-
ing demographic features, underlying diseases, history of immunosuppressive therapy, and
close contact with pigeons.
The mean age of cryptococcal meningitis and cryptococcemia cases was approximately 50
years. Most cases (72.3%–76.6%) occurred in men. The age and gender distributions were simi-
lar between cases of cryptococcal meningitis and those of cryptococcemia (Table 1). The ma-
jority of patients younger than 40 years had AIDS, whereas the older age (50 years) group
consisted primarily of non-AIDS patients.
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AIDS (41.6%–44.7%) was the most common underlying condition in both the cryptococcal
meningitis cases and the cryptococcemia cases, followed by immunosuppressive therapy
(23.8%–27.7%), cardiovascular diseases (20.8%–27.7%), autoimmune diseases (12.9%–21.3%),
decompensated liver cirrhosis (7.9%–17.0%), and diabetes mellitus (15.8%–17.0%). The pat-
tern of underlying conditions was not significantly different between the cryptococcal meningi-
tis cases and the cryptococcemia cases (Table 1).
In-hospital mortality was significantly higher in cryptococcemia cases compared with cryp-
tococcal meningitis cases (23/47 [48.9%] vs. 28/101 [27.7%], p = 0.016). Of the 101 patients
with cryptococcal meningitis, 32 (32%) had cryptococcemia, for whom in-hospital mortality
occurred at double the rate of those who had cryptococcal meningitis but did not have crypto-
coccemia (14/32 [43.8%] vs. 14/69 [20.3%], p = 0.027). Cases with decompensated liver cirrho-
sis had a particularly high mortality, compared with cases without decompensated liver
cirrhosis, in both cryptococcal meningitis group (6/8 [75.0%] vs. 22/93 [23.7%], p = 0.005) and
cryptococcemia group (6/8 [75.0%] vs. 17/39 [43.6%], p = 0.137).
Table 2 shows the concomitantly involved sites in the 47 patients with cryptococcemia.
Those with AIDS (n = 21) were more likely to have culture-proven meningitis than those with
decompensated liver cirrhosis (n = 8) (19/21 [90%] vs. 3/8 [44.4%], p = 0.008). However, those
patients with decompensated liver cirrhosis were significantly less likely than patients with
AIDS to undergo a lumbar puncture for a CSF study (5/8 [62.5%] vs. 21/21 [100%], p = 0.023;
Table 2).
Fig 1. Flow chart of the recruitment of cases.
doi:10.1371/journal.pone.0119090.g001
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Table 1. Epidemiological characteristics of 101 Cryptococcus neoformans meningitis cases and 47 C. neoformans fungemia cases.
Characteristics C. neoformans meningitis (N = 101) C. neoformans fungemia (N = 47) p-value
Age, range, years 20–86 24–79
Age, mean ± SD, years 49.8 ± 17.2 51.6 ± 18.2
Male 73 (72.3) 36 (76.6) 0.58
AIDS 42 (41.6) 21 (44.7) 0.72
Immunosuppressive therapy 24 (23.8) 13 (27.7) 0.68
CMI-suppressive therapy 23 (22.8) 13 (27.7) 0.52
Regimens without CAs 19 (18.8) 11 (23.4) 0.52
Prednisolonea 11 5
Methylprednisolonea 1 1
Prednisolonea + azathioprine 4 3
Prednisolonea + chlorambucil 1 0
Prednisolonea + cyclophosphamide 1 1
Prednisolonea + rituximab + etoposide 1 0
Dexamethasonea + mephalan 0 1
CA-based regimens 4 (4.0) 2 (4.3) 1.00
Tarcolimus + prednisoloneb + mycophenolate mofetil 3 1
Cyclosporin + prednisoloneb 1 0
Cyclosporin + methylprednisoloneb 0 1
Cytotoxic chemotherapy 5 (5.0) 3 (6.4) 0.71
Cardiovascular disease 21 (20.8) 13 (27.7) 0.36
Autoimmune diseases 13 (12.9) 10 (21.3) 0.19
Decompensated liver cirrhosis 8 (7.9) 8 (17.0) 0.10
Diabetes mellitus 16 (15.8) 8 (17.0) 0.86
Gastrointestinal diseases 6 (5.9) 6 (12.8) 0.16
Lymphoma 4 (4.0) 3 (6.4) 0.68
Leukemia/myeloma 3 (3.0) 3 (6.4) 0.38
Cancer 14 (13.9) 6 (12.8) 1.00
Solid organ transplantation 4† (4.0) 1* (2.1) 1.00
Bone marrow/stem cell transplantation 0 (0) 0 (0) -
Uremia 2 (2.0) 1 (2.1) 1.00
COPD 0 (0) 0 (0) -
Asthma 0 (0) 0 (0) -
Bronchiectasis 0 (0) 0 (0) -
Pneumoconiosis 1 (1) 0 (0) 1.00
Close contact with pigeons 5 (5.0) 0 (0) 0.31
Data are no. (%) of patients, unless otherwise indicated. AIDS: acquired immunodeficiency syndrome; CAs: calcineurin inhibitors; CMI: cell-mediated
immunity; COPD: chronic obstructive pulmonary disease.
†Heart (n = 2), kidney (n = 1), liver (n = 1).
*Heart (n = 1).
a Mean dosage of steroid in CMI-suppressive regimens without CA: equivalent dose of prednisolone 20 mg/day in meningitis cases and 30 mg/day in
cryptococcemia cases.
b Mean dosage of steroid in CA-based regimens: equivalent dose of prednisolone 10 mg/day in meningitis cases and 55 mg/day in cryptococcemia cases.
doi:10.1371/journal.pone.0119090.t001
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Risk Factors for Cryptococcal Meningitis
The significant variables in the univariate analysis included AIDS, decompensated liver cirrho-
sis, CMI-suppressive regimens without CA, cytotoxic chemotherapy, cardiovascular disease,
autoimmune diseases, cancer, and close contact with pigeons (Table 3). Diabetes mellitus was
not a risk factor (crude odds ratio [OR] = 1.5; 95% CI: 0.7 to 3.2; p = 0.389). Multivariate re-
gression analysis revealed the following three independent risk factors for cryptococcal menin-
gitis: decompensated liver cirrhosis (adjusted OR = 8.5; 95% CI: 1.6 to 62.3; p = 0.008), AIDS
(adjusted OR = 181.4; 95% CI: 28.2 to>999; p< 0.001), and CMI-suppressive regimens with-
out CAs (adjusted OR = 15.9; 95% CI: 4.9 to 68.2; p< 0.001) (Table 4). Close contact with pi-
geons was a risk factor for cryptococcal meningitis in the univariate analysis (crude OR = 13.5;
95% CI: 1.8 to1; p = 0.008); however, this variable did not enter the final model.
Risk Factors for Cryptococcemia
Univariate analyses identified AIDS, decompensated liver cirrhosis, CMI-suppressive regimens
without CAs, autoimmune diseases, and cancer as the significant variables (Table 5). Diabetes
mellitus was not a risk factor (crude OR = 1.4; 95% CI: 0.5 to 3.5; p = 0.650). Decompensated
liver cirrhosis (adjusted OR = 23.8; 95% CI: 3.4 to 340.9; p< 0.001), AIDS (adjusted OR =
216.3; 95% CI: 24.2 to>999; p< 0.001), CMI-suppressive regimens without CAs (adjusted
OR = 7.3; 95% CI: 1.1 to 57.5; p = 0.034), and autoimmune diseases (adjusted OR = 9.3; 95%
CI: 1.1 to 135.7; p = 0.038) were independent risk factors for cryptococcemia (Table 6).
Discussion
To our knowledge, the present study is the first hospital-based, case-control study to investigate
the risk factors for the occurrence of invasive C. neoformans diseases. The results showed that
AIDS, decompensated liver cirrhosis, and CMI-suppressive regimens without CAs were three
independent risk factors for cryptococcal meningitis and cryptococcemia in Taiwan. Moreover,
autoimmune disease was an independent risk factor for cryptococcemia. On the other hand,
Table 2. Characteristics of the 47 patients with cryptococcemia.
Involved sites† All cases (N = 47)
(%)
Decompensated cirrhosis (N = 8)
(%)
AIDS (N = 21)
(%)
p-value ξ (Decompensated cirrhosis vs.
AIDS)
Meningitis 32 (68.1) 3 (37.5) 19 (90) 0.008
CSF culture (+) 31 (66.0) 3 (37.5) 19 (90) -
CSF Cryptococcal Ag
(+)
32 (68.1) 3 (37.5) 19 (90) -
CSF culture (−) 5 (10.6) 2 (25.0) 2 (10) 0.568
CSF not checked 8 (17.0) 3 (37.5) 0 (0) 0.023
Peritonitis 3 (6.4) 3 (37.5) 1 (5) 0.076
Pleurisy 3 (6.4) 2 (25.0) 0 (0) 0.089
Lung (pathology-proven) 2 (4.3) 0 (0) 0 (0) 1.000
Urine 7 (14.9) 3 (37.5) 2 (10) 0.112
Bone and soft tissue 1 (2.1) 0 (0) 0 (0) 1.000
PTCD 1 (2.1) 1 (12.5) 0 (0) 0.310
PTCD: Percutaneous transhepatic cholangio-drainage.
ξ p-values were computed using Fisher’s exact test to compare cryptococcemia cases with decompensated liver cirrhosis and cases with AIDS.
†Culture-proven, unless otherwise indicated.
doi:10.1371/journal.pone.0119090.t002
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diabetes mellitus and other medical conditions were not found to be risk factors of cryptococcal
meningitis or cryptococcemia.
Both cryptococcal meningitis and cryptococcemia were included in the present study as in-
vasive C. neoformans diseases cases. We had previously reported that cryptococcemia is a ful-
minant form of cryptococcal disease with a high acute mortality rate, especially for those with
liver cirrhosis [25]. The present study further highlights that patients with cryptococcemia
Table 3. Univariate analyses of variables associated with cryptococcal meningitis.
Variables Cases (N = 101) Controls (N = 266) Unadjusted OR (95% CI) p-value
Decompensated liver cirrhosis 8 4 6.5 (1.5–39.4) 0.009
AIDS 42 3 118.8 (20.0–>999) <0.001
Immunosuppressive therapy 24 57 - -
CMI-suppressive therapy 23 15 - -
Regimens without CAs# 19# 10# 5.5 (2.3–13.9) <0.001
CA-based regimens 4 5 1.7 (0.3–8.1) 0.630
Cytotoxic chemotherapy 5 47 0.2 (0.1–0.7) 0.002
Solid organ transplantation 4† 5* 1.9 (0.4–8.8) 0.556
Bone marrow/stem cell transplantation 0 1 2.0 (0–78) 1.000
Diabetes mellitus 16 30 1.5 (0.7–3.2) 0.389
Cardiovascular disease 21 83 0.5 (0.2–0.9) 0.026
Uremia 2 4 1.2 (0.1–8.9) 1.000
Gastrointestinal diseases 6 24 0.9 (0.3–2.5) 1.000
Autoimmune diseases 13 8 4.6 (1.7–12.9) 0.001
COPD 0 5 0.6 (0–3.3) 0.655
Asthma 0 5 0.4 (0–2.1) 0.379
Bronchiectasis 0 2 1.7 (0–21.3) 1.000
Pneumoconiosis 1 0 2.0 (0.1–1) 0.667
Lymphoma 4 5 2.2 (0.4–10.3) 0.422
Leukemia/myeloma 3 5 2.8 (0.5–15.6) 0.271
Cancer 14 85 0.3 (0.1–0.6) <0.001
Others (GIST/sarcoma/thymoma) 0 5 0.5 (0–3.7) 0.546
Close contact with pigeons 5 0 13.5 (1.8–1) 0.008
CMI: cell-mediated immunity; CAs: calcineurin inhibitors; COPD: chronic obstructive pulmonary disease; GIST: gastrointestinal stromal tumor.
†Heart (n = 2), kidney (n = 1), liver (n = 1).
* Heart (n = 2), kidney (n = 2), liver (n = 1).
# The mean dosage of steroid was significantly higher in cases received CMI-suppressive regimens without CA (n = 19) than that in controls received
CMI-suppressive regimens without CA (n = 10) (equivalent dose of prednisolone: 20 vs. 5.4 mg/day, p = 0.041).
doi:10.1371/journal.pone.0119090.t003
Table 4. Independent risk factors for cryptococcal meningitis.
Variables Adjusted OR (95% CI) p-value
AIDS 181.4 (28.2–>999) <0.001
CMI-suppressive regimens without CAs 15.9 (4.9–68.2) <0.001
Decompensated liver cirrhosis† 8.5 (1.6–62.3) 0.008
AIDS: acquired immunodeficiency syndrome. CMI: cell-mediated immunity; CAs: calcineurin inhibitors.
†Decompensated liver cirrhosis: Child-Pugh score of B or C.
doi:10.1371/journal.pone.0119090.t004
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have an approximately two-fold higher mortality rate than patients who have had cryptococcal
meningitis unaccompanied by cryptococcemia.
AIDS, the end stage of HIV infection [27], is characterized by profound impairment of CMI
[5–11], which predisposes people to invasive C. neoformans diseases. Extrapulmonary crypto-
coccosis is an AIDS-defining illness [27]. Cryptococcal meningitis is one of the most common
opportunistic infections in patients who develop AIDS [3,4]. The wide use of highly active
Table 5. Univariate analyses of variables associated with cryptococcemia.
Variables Cases (N = 47) Controls (N = 188) Unadjusted OR (95% CI) p-value
Decompensated liver cirrhosis 8 4 13.7 (2.7–134.6) <0.001
AIDS 21 2 81.5 (13.1–>999) <0.001
Immunosuppressive therapy 13 40 - -
CMI-suppressive therapy 13 11 - -
Regimens without CAs# 11# 9# 5.7 (2.0–17.6) <0.001
CA-based regimens 2 2 4.0 (0.3–55.2) 0.362
Cytotoxic chemotherapy 3 31 0.3 (0.1–1.2) 0.106
Solid organ transplantation 1† 2* 2.0 (0.03–38.4) 0.980
Bone marrow/stem cell transplantation 0 0 - -
Diabetes mellitus 8 25 1.4 (0.5–3.5) 0.650
Cardiovascular disease 13 69 0.6 (0.2–1.4) 0.252
Uremia 1 5 0.8 (0.02–8.4) 1.000
Gastrointestinal diseases 6 21 1.2 (0.3–3.6) 0.935
Autoimmune diseases 10 9 5.8 (1.9–19.9) 0.002
COPD 0 6 0.5 (0–2.6) 0.492
Asthma 0 5 0.6 (0–3.3) 0.655
Bronchiectasis 0 1 4.0 (0–76) 1.000
Pneumoconiosis 0 0 - -
Lymphoma 3 5 2.6 (0.4–15.8) 0.394
Leukemia/myeloma 3 2 6.0 (0.7–71.8) 0.116
Cancer 6 61 0.3 (0.1–0.8) 0.008
Others (GIST/sarcoma/thymoma) 0 3 1.0 (0–6.9) 1.000
CMI: cell-mediated immunity; CAs: calcineurin inhibitors; COPD: chronic obstructive pulmonary disease; GIST: gastrointestinal stromal tumor.
†Heart (n = 1).
*kidney (n = 1), liver (n = 1).
# The mean dosage of steroid was significantly higher in cases CMI-suppressive regimens without CA (n = 11) than that in controls received CMI-
suppressive regimens without CA (n = 9) (equivalent dose of prednisolone: 30 mg/day vs. 5 mg/day, p = 0.003).
doi:10.1371/journal.pone.0119090.t005
Table 6. Independent risk factors for cryptococcemia.
Variables Adjusted OR (95% CI) p-value
AIDS 216.3 (24.2–>999) <0.001
CMI-suppressive regimens without CAs 7.3 (1.1–57.5) 0.034
Autoimmune diseases 9.3 (1.1–135.7) 0.038
Decompensated liver cirrhosis† 23.8 (3.4–340.9) <0.001
AIDS: acquired immunodeficiency syndrome. CMI: cell-mediated immunity. CAs: calcineurin inhibitors.
†Decompensated liver cirrhosis: Child-Pugh score of B or C.
doi:10.1371/journal.pone.0119090.t006
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antiretroviral therapy (HAART), which can help prevent the development of AIDS if initiated
early in the course of HIV infection, led to a decline in the number of C. neoformans cases in
North America and Western Europe [20,31]. Our study provides new epidemiologic evidence
that confirmed that AIDS is an important risk factor for the occurrence of invasive C. neofor-
mans diseases. Our results support the World Health Organization’s current advice on the pre-
vention of cryptococcal diseases in HIV-infected patients, which emphasizes that the most
important and cost-effective strategy is the early initiation of ART through expanded HIV test-
ing and scaled-up access to HAART [4].
CMI has been shown to play a critical role in the host’s defense against C. neoformans in an-
imal models [12–17]. Our study confirmed that CMI-suppressive therapy increases the risk of
invasive C. neoformans diseases in humans. Of particular interest is the observation that only
the regimen that did not contain a calcineurin inhibitor was found to be a significant risk fac-
tor. The virulence of C. neoformans depends on fungal calcineurin [32]. Calcineurin inhibitors,
such as cyclosporine and tacrolimus, have in vitro antifungal activity against C. neoformans
[29,33] and may mitigate the increased risk of C. neoformans diseases under CMI-suppressive
therapy. However, because of the small numbers of subjects receiving cyclosporine- or tacroli-
mus-based CMI-suppressive regimens in the present study, whether such regimens actually
did confer a lower risk of invasive C. neoformans diseases remains statistically inconclusive and
needs to be clarified in future studies. It is advisable that all patients receiving CMI-suppressive
therapy, regardless of their regimens, be educated to avoid exposure to environmental sources
of C. neoformans, such as pigeons and Eucalyptus trees. Physicians should be aware of the risk
of invasive C. neoformans diseases in these patients. Early diagnosis and prompt antifungal
treatment can be life-saving.
Patients with autoimmune diseases, such as systemic lupus erythematosus (SLE), have been
demonstrated to have defects in the functions of phagocytes, humoral immunity, and cellular
immunity [34]. In a study involving 150 SLE patients, the functional impairment of T helper
cells was found to be correlated with disease activity rather than the medication doses [34],
which indicates that autoimmune disease per se is an independent factor that contributes to de-
creased CMI. In the present study, we confirmed autoimmune disease is an independent risk
factor for the occurrence of cryptococcemia.
In the present study, we confirmed that decompensated liver cirrhosis is an independent
risk factor for the occurrence of invasive C. neoformans disease. The pathogenesis mechanism
could involve multiple aspects. First, although C. neoformans typically enters the human body
via inhalation through the respiratory system, people may become infected by ingesting con-
taminated food [35]. The presence of collateral circulation in decompensated liver cirrhosis al-
lows for ingested C. neoformans to bypass the liver scavenger system and directly enter the
circulatory system, thereby causing cryptococcemia and being further disseminated into the
central nervous system. In addition, deficiencies in complement [36] and chemotaxis [37] as
well as lymphocyte hyporesponsiveness [38] have been reported. The impaired innate and cell-
mediated immunity in persons with decompensated liver cirrhosis not only contributes to an
increased risk for invasive cryptococcal disease, but also a high risk of mortality once the dis-
ease occurs [25]. The high mortality of patients with decompensated liver cirrhosis in the pres-
ent study (6/8 [75%] in cryptococcal meningitis cases and 6/8 [75%] in cryptococcemia cases)
is consistent with that reported by Jean et al. (9/11 [82%]) [25] and Singh et al. (26/32 [81%])
[18]. Whether early recognition and prompt antifungal therapy can reduce this high mortality
remains to be determined.
Diabetes mellitus was present in 8.5% to 33% of cryptococcosis cases in reported series
[21,23,26,39] and in 15.8% of cryptococcal meningitis cases and 17.0% of cryptococcemia cases
in the present study. Nevertheless, diabetes mellitus is a relative common condition in
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population, and the prevalence increases with age (7.56% among Taiwanese men aged 40–59,
19.97% among Taiwanese men aged 60–79, in Year 2009) [40]. This highlights the necessity of
using an age-matched control group in evaluating the role of diabetes. The lack of association
between diabetes mellitus and cryptococcosis in the present case-control study implies that dia-
betes mellitus was a comorbidity in those with two diseases, and that diabetic patients are actu-
ally not at increased risk of invasive cryptococcal diseases.
The strengths of the present study include the use of a computerized inpatient registry and
ICD-9 diagnostic codes to identify all cases of invasive C. neoformans diseases during the study
period and the verification of the diagnoses through review of medical records and microbio-
logic reports. In addition, a standard data format was used to systematically collect information
on potential risk factors from medical records. This method circumvents patient recall bias,
which is commonly encountered in case-control studies.
Our study has several limitations. First, because the medical records may not have included
comprehensive information on casual exposure to pigeons or Eucalyptus trees, we were unable
to confirm that such exposure is a risk factor for invasive C. neoformans disease. Second, close
contact with pigeons (including raising pigeons or visiting pigeon farms; n = 5) likely is an im-
portant factor in acquiring C. neoformans disease, and it was shown to be a risk factor in the
univariate analysis (OR = 13.5, p = 0.008). However, the small number of cases limits the statis-
tical power of the multivariate analysis to implicate close contact with pigeons as an indepen-
dent risk factor.
In conclusion, AIDS, decompensated liver cirrhosis, CMI-suppressive regimens without
CAs, and autoimmune diseases are four independent risk factors for the occurrence of invasive
C. neoformans diseases, while diabetes mellitus and other medical conditions are not. The pres-
ent study confirms previous clinical observations and animal studies on the critical role of im-
paired cell-mediated immunity in the pathogenesis of invasive C. neoformans diseases, and
provides a more precise characterization of high-risk individuals.
Supporting Information
S1 Dataset. Cryptococcal meningitis and cryptococcemia dataset.
(RAR)
Author Contributions
Conceived and designed the experiments: YYL SS CTF. Performed the experiments: YYL CTF.
Analyzed the data: YYL CTF. Wrote the paper: YYL SS CTF.
References
1. Hansemann DV (1905) Uber eine bisher nicht beobachtete Gehirner Krankung durch Hefen. Verh
Dtsch Ges Pathol 9: 21–24.
2. Mitchell TG, Perfect JR (1995) Cryptococcosis in the era of AIDS―100 years after the discovery ofCryp-
tococcus neoformans. Clin Microbiol Rev 8: 515–548. PMID: 8665468
3. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM (2009) Estimation of the
current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23: 525–
530. doi: 10.1097/QAD.0b013e328322ffac PMID: 19182676
4. World Health Organization (2011) Rapid advice: diagnosis, prevention and management of cryptococ-
cal disease in HIV-infected adults, adolescents and children. Geneva.
5. Kovacs JA, Kovacs AA, Polis M, Wright WC, Gill VJ, Tuazon CU, et al. (1985) Cryptococcosis in the ac-
quired immunodeficiency syndrome. Ann Intern Med 103: 533–538. PMID: 3898951
6. Eng RH, Bishburg E, Smith SM, Kapila R (1986) Cryptococcal infections in patients with acquired im-
mune deficiency syndrome. Am J Med 81: 19–23. PMID: 3022581
Risk Factors for InvasiveCryptococcus neoformans Diseases
PLOS ONE | DOI:10.1371/journal.pone.0119090 March 6, 2015 11 / 13
7. Gal AA, Koss MN, Hawkins J, Evans S, Einstein H (1986) The pathology of pulmonary cryptococcal in-
fections in the acquired immunodeficiency syndrome. Arch Pathol Lab Med 110: 502–507. PMID:
3754723
8. Shimizu RY, Howard DH, Clancy MN (1986) The variety of Cryptococcus neoformans in patients with
AIDS. J Infect Dis 154: 1042. PMID: 3537151
9. Zuger A, Louie E, Holzman RS, Simberkoff MS, Rahal JJ (1986) Cryptococcal disease in patients with
the acquired immunodeficiency syndrome. diagnostic features and outcome of treatment. Ann Intern
Med 104: 234–240. PMID: 3946951
10. Chuck SL, Sande MA (1989) Infections with Cryptococcus neoformans in the acquired immunodefi-
ciency syndrome. N Engl J Med 321: 794–799. PMID: 2671735
11. Zoller WG, Kellner H, Goebel FD, Schmiedtke K, Holecek B, Staib F, et al. (1989)Cryptococcus neo-
formansmeningoencephalitis and multiple infections in AIDS. Klin Wochenschr 67: 598–604. PMID:
2545969
12. Graybill JR, Drutz DJ (1978) Host defense in cryptococcosis. II. Cryptococcosis in the nude mouse.
Cell Immunol 40: 263–274. PMID: 363279
13. Cauley LK, Murphy JW (1979) Response of congenitally athymic (nude) and phenotypically normal
mice to Cryptococcus neoformans infection. Infect Immun 23: 644–651. PMID: 313367
14. Nishimura K, Miyaji M (1979) Histopathological studies on experimental cryptococcosis in nude mice.
Mycopathologia 68: 145–153. PMID: 316872
15. Salkowski CA, Balish E (1990) Pathogenesis of Cryptococcus neoformans in congenitally immunode-
ficient beige athymic mice. Infect Immun 58: 3300–3306. PMID: 2401566
16. Salkowski CA, Balish E (1991) Inflammatory responses to cryptococcosis in congenitally athymic mice.
J Leukoc Biol 49: 533–541. PMID: 2026961
17. Salkowski CA, Balish E (1991) Cutaneous cryptococcosis in athymic and beige-athymic mice. Infect
Immun 59: 1785–1789. PMID: 1850380
18. Singh N, Husain S, De Vera M, Gayowski T, Cacciarelli TV (2004) Cryptococcus neoformans infection
in patients with cirrhosis, including liver transplant candidates. Medicine (Baltimore) 83: 188–192.
PMID: 15118545
19. Pfaller MA, Diekema DJ (2010) Epidemiology of invasive mycoses in North America. Crit Rev Microbiol
36: 1–53. doi: 10.3109/10408410903241444 PMID: 20088682
20. Mirza SA, Phelan M, Rimland D, Graviss E, Hamill R, Brandt ME, et al. (2003) The changing epidemiol-
ogy of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan
areas, 1992–2000. Clin Infect Dis 36: 789–794. PMID: 12627365
21. Kiertiburanakul S, Wirojtananugoon S, Pracharktam R, Sungkanuparph S (2006) Cryptococcosis in
human immunodeficiency virus-negative patients. Int J Infect Dis 10: 72–78. PMID: 16288998
22. Lee TK, Chiu WS, Hsu CJ, Yang SP (1959) Cryptococcosis: a review with two case reports. J Formo-
san Med Assoc 58: 567–578.
23. Shih CC, Chen YC, Chang SC, Luh KT, HsiehWC (2000) Cryptococcal meningitis in non-HIV-infected
patients. QJM 93: 245–251. PMID: 10787453
24. Sun HY, Hung CC, Chang SC (2004) Management of cryptococcal meningitis with extremely high intra-
cranial pressure in HIV-infected patients. Clin Infect Dis 38: 1790–1792. PMID: 15227631
25. Jean SS, Fang CT, ShauWY, Chen YC, Chang SC, Hsueh PR, et al. (2002) Cryptococcaemia: clinical
features and prognostic factors. QJM 95: 511–518. PMID: 12145390
26. Tseng HK, Liu CP, Ho MW, Lu PL, Lo HJ, Lin YH, et al. (2013) Microbiological, epidemiological, and
clinical characteristics and outcomes of patients with cryptococcosis in Taiwan, 1997–2010. PLoS One
8: e61921. doi: 10.1371/journal.pone.0061921 PMID: 23613973
27. Centers for Diseases Control and Prevention (1992) 1993 revised classification system for HIV infec-
tion and expanded surveillance case definition for AIDS among adolescents and adults. MMWR
RecommRep 41: 1–19. PMID: 1480128
28. Child CG, Turcotte JG (1964) Surgery and portal hypertension. Major Probl Clin Surg 1: 1–85. PMID:
4950264
29. Singh N, Alexander BD, Lortholary O, Dromer F, Gupta KL, John GT, et al. (2007) Cryptococcus neo-
formans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis
195: 756–764. PMID: 17262720
30. American Diabetes Association (2006) Diagnosis and classification of diabetes mellitus. Diabetes Care
29 (Suppl 1): S43–48. PMID: 16373932
Risk Factors for InvasiveCryptococcus neoformans Diseases
PLOS ONE | DOI:10.1371/journal.pone.0119090 March 6, 2015 12 / 13
31. Dromer F, Mathoulin-Pelissier S, Fontanet A, Ronin O, Dupont B, Lortholary O, et al. (2004) Epidemiol-
ogy of HIV-associated cryptococcosis in France (1985–2001): comparison of the pre- and post-HAART
eras. AIDS 18: 555–562. PMID: 15090810
32. Odom A, Muir S, Lim E, Toffaletti DL, Perfect J, Heitman J, et al. (1997) Calcineurin is required for viru-
lence of Cryptococcus neoformans. EMBO J 16: 2576–2589. PMID: 9184205
33. Cruz MC, Del Poeta M, Wang P, Wenger R, Zenke G, Quesniaux VF, et al. (2000) Immunosuppressive
and nonimmunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogenCryp-
tococcus neoformans via cyclophilin-dependent inhibition of calcineurin. Antimicrob Agents Chemother
44: 143–149. PMID: 10602736
34. Bermas BL, Petri M, Goldman D, Mittleman B, Miller MW, Stocks NI, et al. (1994) T helper cell dysfunc-
tion in systemic lupus erythematosus (SLE): relation to disease activity. J Clin Immunol 14: 169–177.
PMID: 7929693
35. Jean SS, Wang JL, Wang JT, Fang CT, Chen YC, Chang SC. (2005)Cryptococcus neoformans perito-
nitis in two patients with liver cirrhosis. J Formos Med Assoc 104: 39–42. PMID: 15660176
36. Akalin HE, Laleli Y, Telatar H (1985) Serum bactericidal and opsonic activities in patients with non-alco-
holic cirrhosis. QJM 56: 431–437. PMID: 3901076
37. DeMeo AN, Andersen BR, English DK, Peterson J (1972) Defective chemotaxis associated with a
serum inhibitor in cirrhotic patients. N Engl J Med 286: 735–740. PMID: 5025776
38. Holdstock G, Chastenay BF, Krawitt EL (1982) Studies on lymphocyte hyporesponsiveness in cirrho-
sis: the role of increased monocyte suppressor cell activity. Gastroenterology 82: 206–212. PMID:
6459260
39. Chuang YM, Ho YC, Chang HT, Yu CJ, Yang PC, Hsueh PR (2008) Disseminated cryptococcosis in
HIV-uninfected patients. Eur J Clin Microbiol Infect Dis 27: 307–310. PMID: 18157678
40. Jiang YD, Chang CH, Tai TY, Chen JF, Chuang LM (2012) Incidence and prevalence rates of diabetes
mellitus in Taiwan: analysis of the 2000–2009 Nationwide Health Insurance database. J Formos Med
Assoc 111: 599–604. doi: 10.1016/j.jfma.2012.09.014 PMID: 23217595
Risk Factors for InvasiveCryptococcus neoformans Diseases
PLOS ONE | DOI:10.1371/journal.pone.0119090 March 6, 2015 13 / 13
